NCT06470750 Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
| NCT ID | NCT06470750 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Prostate Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 77 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 77 participants in total. It began in 2024-07-25 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.
Eligibility Criteria
Inclusion Criteria: * GROUP 1 FOCUS GROUPS: * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer * GROUP 1 SURVEYS: * Are 18 years of age or older * Have histologic evidence of prostate adenocarcinoma * Are requiring, have required, or will require prostate cancer treatment * Have an understanding of the protocol and its requirements * Are willing to fill in a questionnaire and participate in a focused interview * Are able and willing to sign an informed consent * GROUP 1 INTERVIEWS: * Enrollment in the survey phase of the protocol * GROUP 2: * Are 18 years of age or older * Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have histologic evidence of prostate adenocarcinoma * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel) * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW) * Have an understanding of the protocol and its requirements * Are able and willing to sign informed consent Exclusion Criteria: * GROUP 1 FOCUS GROUPS: * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system * GROUP 1 SURVEYS: * Do not identify as Black men * Have not been diagnosed with prostate cancer * GROUP 1 INTERVIEWS: * Not enrolled in the survey phase of the protocol * GROUP 2: * Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges) * Have not been diagnosed with histologic evidence of prostate adenocarcinoma * Are not requiring active standard anti-cancer therapy
Contact & Investigator
Roxana S. Dronca, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06470750 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06470750 currently recruiting?
Yes, NCT06470750 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT06470750 trial being conducted?
This trial is being conducted at Jacksonville, United States.
Who is sponsoring the NCT06470750 clinical trial?
NCT06470750 is sponsored by Mayo Clinic. The principal investigator is Roxana S. Dronca, MD at Mayo Clinic. The trial plans to enroll 77 participants.